ArticleSignal transduction and targeted therapy2023
Elevated peripheral levels of receptor-interacting protein kinase 1 (RIPK1) and IL-8 as biomarkers of human amyotrophic lateral sclerosis.
Open access · goldAbstract read
In one paragraph
Article in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 15 citations in OpenAlex.
- Mechanisms, regulation and clinical relevance of necroptosis.Nature reviews. Molecular cell biology · 2026Review
- LXR Pathway Activation by T0901317: A Novel Potential Experimental Strategy for ALS-Related Cognitive and Motor Impairments via Suppression of Necroptosis-associated RIPK1/RIPK3/MLKL Markers.Molecular neurobiology · 2026Article
- Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression.The Journal of clinical investigation · 2026Article
- Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression.bioRxiv : the preprint server for biology · 2026Article
- PANoptosis in neurological disorders: from inflammatory cell death mechanisms to neuroprotective strategies.Frontiers in neuroscience · 2026Review
- Amyotrophic lateral sclerosis in Mainland China: clinical translational challenges and opportunities.Current opinion in neurology · 2025Review
- Targeting the RAGE-RIPK1 binding site attenuates diabetes-associated cognitive deficits.Journal of neuroinflammation · 2025Article
- RIPK1: A Promising Target for Intervention Neuroinflammation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Review
- The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1.ACS medicinal chemistry letters · 2025Article
- Exploring epigenetic modifications as potential biomarkers and therapeutic targets in amyotrophic lateral sclerosis.Journal of neurology · 2025Review
- Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis.Nature reviews. Neurology · 2025Review
- Admission Serum Receptor-Interacting Protein Kinase-1 as a Biomarker of Severity and a Prognostic Factor in Aneurysmal Subarachnoid Hemorrhage.International journal of general medicine · 2025Article
- Biomarkers to predict the severity of acute pancreatitis.Frontiers in medicine · 2025Review
- The interplay between α-synuclein aggregation and necroptosis in Parkinson's disease: a spatiotemporal perspective.Frontiers in neuroscience · 2025Review
- Glioinflammation: disease-associated microglia and astrocytes in psychiatric disorders, neurodegeneration, and senescence.Frontiers in cellular neuroscience · 2025Review
- Serum RIPK1, Acute Lung Injury, and Outcomes in Severe Traumatic Brain Injury: A Multicenter Prospective Study.Therapeutics and clinical risk management · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Jun Wei *Institute of Neural Regeneration and Repair and Department of Neurology, The First College of Clinical Medical Science, Yichang Central Hospital, College of Basic Medical Science, China Three Gorges University, Hubei Province Clinical Medical Research Center for Rare Diseases of Nervous System, Yichang, 443000, China.
Min Li *Institute of Neural Regeneration and Repair and Department of Neurology, The First College of Clinical Medical Science, Yichang Central Hospital, College of Basic Medical Science, China Three Gorges University, Hubei Province Clinical Medical Research Center for Rare Diseases of Nervous System, Yichang, 443000, China.
Zhi Ye *Institute of Neural Regeneration and Repair and Department of Neurology, The First College of Clinical Medical Science, Yichang Central Hospital, College of Basic Medical Science, China Three Gorges University, Hubei Province Clinical Medical Research Center for Rare Diseases of Nervous System, Yichang, 443000, China.ORCID 0000-0003-0706-2522
Xinqian HuInstitute of Neural Regeneration and Repair and Department of Neurology, The First College of Clinical Medical Science, Yichang Central Hospital, College of Basic Medical Science, China Three Gorges University, Hubei Province Clinical Medical Research Center for Rare Diseases of Nervous System, Yichang, 443000, China.
Xiaoyan HeInstitute of Neural Regeneration and Repair and Department of Neurology, The First College of Clinical Medical Science, Yichang Central Hospital, College of Basic Medical Science, China Three Gorges University, Hubei Province Clinical Medical Research Center for Rare Diseases of Nervous System, Yichang, 443000, China.
Jia WangInstitute of Neural Regeneration and Repair and Department of Neurology, The First College of Clinical Medical Science, Yichang Central Hospital, College of Basic Medical Science, China Three Gorges University, Hubei Province Clinical Medical Research Center for Rare Diseases of Nervous System, Yichang, 443000, China.
Gaofeng ChenInstitute of Neural Regeneration and Repair and Department of Neurology, The First College of Clinical Medical Science, Yichang Central Hospital, College of Basic Medical Science, China Three Gorges University, Hubei Province Clinical Medical Research Center for Rare Diseases of Nervous System, Yichang, 443000, China.
Chengyu ZouInterdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai Key Laboratory of Aging Studies, Shanghai, 201210, China.
Daichao XuInterdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai Key Laboratory of Aging Studies, Shanghai, 201210, China.
Hongbing ZhangState Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0001-6291-1027
Junying YuanInterdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai Key Laboratory of Aging Studies, Shanghai, 201210, China. Junying_yuan@sioc.ac.cn.
Yunhong ZhaInstitute of Neural Regeneration and Repair and Department of Neurology, The First College of Clinical Medical Science, Yichang Central Hospital, College of Basic Medical Science, China Three Gorges University, Hubei Province Clinical Medical Research Center for Rare Diseases of Nervous System, Yichang, 443000, China. yzha7808@ctgu.edu.cn.
China Three Gorges University · CNChinese Academy of Sciences · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN
Funding
Health and Family Planning Commission of Hubei Province (Hubei Provincial Health Department) WJ2021M257National Natural Science Foundation of China (National Science Foundation of China) 32070737National Natural Science Foundation of China (National Science Foundation of China) 82188101, 91849204, 21837004, 92049303 and 32170755Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission) 2019SHZDZX02Shanghai Science and Technology Development Foundation (Shanghai Science and Technology Development Fund) 20JC1411600Shanghai Science and Technology Development Foundation (Shanghai Science and Technology Development Fund) 20QA1411500
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating fatal neurodegenerative disease with no cure. Receptor-interacting protein kinase 1 (RIPK1) has been proposed to mediate pathogenesis of ALS. Primidone has been identified as an old drug that can also inhibit RIPK1 kinase. We conducted a drug-repurposing biomarker study of primidone as a RIPK1 inhibitor using SOD1
Indexed as
Amyotrophic Lateral SclerosisNeurodegenerative DiseasesAnimalsBiomarkersHumansInterleukin-8MiceMice, TransgenicMotor NeuronsPrimidoneProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesSuperoxide DismutaseSuperoxide Dismutase-1BiomarkersCXCL8 protein, humanInterleukin-8PrimidoneProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanSuperoxide DismutaseSuperoxide Dismutase-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.